Annual report [Section 13 and 15(d), not S-K Item 405]

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

v3.25.0.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
The components of accrued expenses and other current liabilities are as follows:
As of December 31,
2024 2023
Deferred income - ERC (1)
$ 9,181  $ 10,140 
Goods received not invoiced 4,366  5,019 
Operating lease obligations
 4,966  4,693 
Accrued employee related expenses and liabilities 4,095  4,175 
Acquisition-related milestone accrual (2)
—  4,167 
Accrued interest (2)
1,531  4,106 
Accrued sales and excise taxes 1,928  2,388 
Deferred revenue (loyalty program) 1,321  1,407 
Accrued professional and management fees 470  986 
Contingent consideration liabilities (2)
—  817 
Accrued capital expenditures 461  702 
Other accrued expenses and current liabilities 4,467  5,470 
Total accrued expenses and other current liabilities
 $ 32,786  $ 44,070 
(1)Refer to Note 4 - Prepaid Expenses and Other Current Assets for more information.
(2)Relates to Sammartino in connection with the acquisition of Nature's Remedy in September 2021. Acquisition-related milestone accrual of $5,000 and accrued interest of $3,130 as of December 31, 2024 was classified as other liabilities - non-current in the consolidated balance sheet, since the Company currently has no obligation to pay these amounts within the next 12 months from the balance sheet date. See further discussion of the Sammartino Matter in Note 22 - Commitments and Contingencies.